Yiming Pharmaceuticals: Subsidiary plans to invest 30 million yuan to participate in a 500 million yuan equity investment fund

LightningPacketLoss · 2026-04-08T07:09:22+00:00

Yiming Pharmaceutical announces that its subsidiary, Yiming Haizhong, plans to subscribe for shares of the Louis Ke Teng Opportunity No. 1 Fund, with a target investment of 500 million yuan. The initial committed amount is 164 million yuan, with Yiming Haizhong contributing 30 million yuan from its own funds and serving as a limited partner.

LightningPacketLoss

2026-04-08 07:09:22

Abstract generation in progress

Recently, Yiming Pharmaceutical issued an announcement stating that its subsidiary, Beijing Yiming Haizhong Investment Management Co., Ltd., plans to subscribe for the interests in Luxway Kaiteng Opportunity No. 1 (Wuxi) Equity Investment Partnership (the “Fund”). The Fund’s target subscribed capital contribution is 500 million yuan, with the initial subscribed capital contribution of 164 million yuan. Yiming Haizhong will contribute 30 million yuan from its own funds as a limited partner.

The Fund’s manager is Luxway Kaiteng (Chengdu) Private Fund Management Co., Ltd., and the general partner is Lu Kai (Hainan) Investment Partnership (Limited Partnership).

(Yiming Pharmaceutical announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes